7bit Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (May 5-6) [ ]"Wed, 4 Apr 2007 09:40:00 -0500" On May 5, 2008, the committees will discuss new drug application (NDA) 22-272, OXYCONTIN (oxycodone hydrochloride Tablets, Purdue Pharma L.P., and its safety for the proposed indication of management of moderate to severe pain when a continuous, analgesic is needed for an extended period of time. The characteristics of this formulation are purportedly less easily defeated than other formulations of OXYCONTIN. On May 6, 2008, the committees will discuss supplemental new drug application (sNDA) 21-947/s-005, FENTORA (fentanyl buccal tablet), Cephalon, Inc., and its safety for the proposed indication of breakthrough pain in opioid tolerant non-cancer patients with chronic pain. Update your subscriptions, modify your shopping address, or stop subscriptions at any time on your Purchase onliner Preferences Page [ ]. You will need to use your shopping address to log in. If you have questions or problems with the subscription service, please contact This service is provided to you at no charge by U.S. Food & Drug Administration (FDA) [ ]. [ ] [ ] GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) . 5600 Fishers Lane . Rockville MD 20857 . 800-439-1420 7bit Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (May 5-6) body }} }} Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (May 5-6)Wed, 4 Apr 2007 09:40:00 -0500 On May 5, 2008, the committees will discuss new drug application (NDA) 22-272, OXYCONTIN (oxycodone hydrochloride Tablets, Purdue Pharma L.P., and its safety for the proposed indication of management of moderate to severe pain when a continuous, analgesic is needed for an extended period of time. The characteristics of this formulation are purportedly less easily defeated than other formulations of OXYCONTIN. On May 6, 2008, the committees will discuss supplemental new drug application (sNDA) 21-947/s-005, FENTORA (fentanyl buccal tablet), Cephalon, Inc., and its safety for the proposed indication of breakthrough pain in opioid tolerant non-cancer patients with chronic pain. Update your subscriptions, modify your shopping address, or stop subscriptions at any time on your Purchase onliner Preferences Page. You will need to use your shopping address to log in. If you have questions or problems with the subscription service, please contact This service is provided to you at no charge by U.S. Food & Drug Administration (FDA). GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420

... Back to listing 39

... Back to article 7606 | SITEMAP | Next to article 7608 ...

We would like to express our gratitude to all those who are kindly providing this unique content, especially to:

office@a3ides.com
olga@bemobile.md
tirlik@brainchildhunter.com
office@bemobile.md
sharuha@causeni.info
info@webconsulting.md
irina.gorea@bemobile.md
office@milieukontakt.nl
igor.romanyuk@bemobile.com.ua
yuri.sekretar@olympia.net.ua
info@tophost.md
webmoldova@yahoo.com
admin@bemobile.md
webmaster@bemobile.md
emil@a3ides.com
olea@bemobile.md
yuri.sekretar@bemobile.com.ua
contact@a3ides.com
info@a3ides.com
vitaliy.lozovskiy@bemobile.md
drugg83@yahoo.com
rector@usm.md
gaugash@usm.md
acad.rudic@mail.md
acadrudic@yahoo.com
veaceslav.vasilache@gmail.com
s.bakker@milieukontakt.nl
katea.melnicenco@gmail.com
mkoe.moldova@vox.md
musteata@doctor.com
renat.buga@ase.md
s.molenkamp@milieukontakt.nl
si_problemme@mail.ru
willem.tjebbe.oostenbrink@planet.nl

Tag cloud:

Committee, Advisory, indication, application, proposed, discuss, shopping, committees, Administration, Anesthetic, ·, Support, Management, Meeting, characteristics, extended, formulations, formulation, OXYCONTIN., analgesic, defeated, purportedly, Tablets,, continuous,, 22-272,, 09:40:00, OXYCONTIN, (oxycodone, moderate, management,

Similar listing on: